MENU
APR 28, 2021 9:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Combining protein proximity detection with chromogenic multiplex: Discovering the PD1/PDL1 interactions

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Postdoctoral Researcher
    Biography

      Thierry P.P. van den Bosch is a postdoctoral researcher for 3 years at the Erasmus University Medical Center, Rotterdam. In 2014 he graduated from the University of applied science in Leiden specialized as pathology technician. In 2018 he finished his PhD at the Erasmus University Medical Center on the subject: Monocytes and Macrophages in Solid Organ Transplantation. After finishing his PhD, he joined the department of Pathology – PARTS (Pathology and Research Trial Service) where he optimizes and introduces new technologies within the field of pathology and support scientists on specific scientific questions, especially in the field of chromogenic and immunofluorescent multiplexing.


    Abstract

    DISCOVERY Proximity detection is a powerful technique for demonstrating the presence of 2 unique targets in direct proximity of each other in tissue sections. It allows visualization of interacting proteins in distance of 40 nm. Recently this technique became available on the Roche DISCOVERY ULTRA staining platform. With the DISCOVERY Proximity detection you can not only detect the presence/absence of a protein, but also to determine its functional states; i.e., whether it carries post-translational modifications or is present in complex with other proteins, in which cells it is expressed, and in which cell compartments the different states of the protein are present. By having the possibility on the DISCOVERY ULTRA system to add chromogenic IHC multiplexing you can create the advantage of visualizing which cells are undergoing protein interaction. In our recent publication we investigated the interaction between PD1/PDL1 where we studied tumour draining lymph nodes of melanomas and the primary tumours with proximity and chromogenic IHC multiplexing. Drugs targeting the PD1/PDL1 pathway have revolutionized the treatment of multiple cancer types including non-small cell lung cancer, renal cancer, and melanoma with a subset of patients experiencing durable responses. PD1/PDL1 blocking antibodies are believed to act primarily in the tumour microenvironment, by reinvigorating exhausted T cells and thereby reviving pre-existing anti-tumour immunity. In this presentation, we will review this technology by setting up PD1/PDL1 Proximity assay in combination with chromogenic IHC multiplexing with CD8, CD68 and CD11c.

    Learning Objectives:

    1. Obtain knowledge on how to set up the Proximity detection on Roche DISCOVERY ULTRA Platform

    2. Obtain knowledge on how to add chromogenic IHC multiplexing to Proximity detection

    3. Understand PD-1/PD-L1 interactions in Tumor Draining Lymph Nodes (TDLN) but not tumor correlate with prognosis in melanoma


    Show Resources
    You May Also Like
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JAN 21, 2021 8:00 AM PST
    JAN 21, 2021 8:00 AM PST
    Date: January 21, 2021 Time: 8:00am (PST), 11:00am (EST) Today, critical reagent characterization is a key component in the overall workflow to establish robust ligand binding assays (e.g.,...
    Loading Comments...
    Show Resources
    Event Countdown
    • 0 Days
    • 0 Hours
    • 0 Minutes
    • 0 Seconds
    Attendees
    • See more